Literature DB >> 20227391

Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2.

Jun Tao1, Jun-Jian Xiang, Dan Li, Ning Deng, Hong Wang, Yi-Ping Gong.   

Abstract

Compelling evidences suggest that fibroblast growth factor-2 (FGF-2) plays important roles in tumor growth, angiogenesis and metastasis. Molecules blocking the FGF-2 signaling have been proposed as anticancer agents. Through screening of a human scFv phage display library, we have isolated several human single-chain Fv fragments (scFvs) that bind to human FGF-2. After expression and purification in bacteria, one scFv, named 1A2, binds to FGF-2 with a high affinity and specificity, and completes with FGF-2 binding to its receptor. This 1A2 scFv was then cloned into the pIgG1 vector and expressed in 293T cells. The purified hIgG1-1A2 antibody showed a high binding affinity of 8x10(-9)M to rhFGF-2. In a set of vitro assays, it inhibited various biological activities of FGF-2 such as the proliferation, migration and tube formation of human umbilical vein endothelial cells. More importantly, hIgG1-1A2 antibody also efficiently blocked the growth while inducing apoptosis of glioma cells. For the first time, we generated a human anti-FGF-2 antibody with proven in vitro anti-tumor activity. It may therefore present a new therapeutic candidate for the treatment of cancers that are dependent on FGF-2 signaling for growth and survival. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227391     DOI: 10.1016/j.bbrc.2010.03.067

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Novel anti IGFBP2 single chain variable fragment inhibits glioma cell migration and invasion.

Authors:  Shilpa S Patil; Reema Railkar; Monalisa Swain; Hanudatta S Atreya; Rajan R Dighe; Paturu Kondaiah
Journal:  J Neurooncol       Date:  2015-05-06       Impact factor: 4.130

Review 2.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

3.  Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2.

Authors:  Masako Tanaka; Maki Yamaguchi; Masayuki Shiota; Yukiko Kawamoto; Katsuyuki Takahashi; Azusa Inagaki; Mayuko Osada-Oka; Akihito Harada; Hideki Wanibuchi; Yasukatsu Izumi; Katsuyuki Miura; Hiroshi Iwao; Yasuyuki Ohkawa
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08

Review 4.  Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells.

Authors:  Mauricio P Pinto; Paula Sotomayor; Gonzalo Carrasco-Avino; Alejandro H Corvalan; Gareth I Owen
Journal:  Int J Mol Sci       Date:  2016-09-06       Impact factor: 5.923

5.  Inhibition activity of a disulfide-stabilized diabody against basic fibroblast growth factor in lung cancer.

Authors:  Yaxiong Cai; Shuange Yao; Jiangchuan Zhong; Jinxia Zhang; Haowu Jiang; Yanrui Deng; Ning Deng
Journal:  Oncotarget       Date:  2017-03-21

6.  Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity.

Authors:  Julia Chudzian; Anna Szlachcic; Malgorzata Zakrzewska; Miroslawa Czub; Marcin Pustula; Tad A Holak; Jacek Otlewski
Journal:  Int J Mol Sci       Date:  2018-08-21       Impact factor: 5.923

7.  Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.

Authors:  Yanxin Yin; Jia Guo; Fei Teng; Lihua Yu; Yun Jiang; Kun Xie; Ming Jiang; Jianmin Fang
Journal:  Drug Des Devel Ther       Date:  2019-12-10       Impact factor: 4.162

8.  A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth.

Authors:  D Li; X Wei; K Xie; K Chen; J Li; J Fang
Journal:  Br J Cancer       Date:  2014-05-29       Impact factor: 7.640

9.  Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer.

Authors:  Yaxiong Cai; Jinxia Zhang; Xuejun Lao; Haowu Jiang; Yunfei Yu; Yanrui Deng; Jiangchuan Zhong; Yiye Liang; Likuan Xiong; Ning Deng
Journal:  Cancer Sci       Date:  2016-07-26       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.